← Back to Clinical Trials
Recruiting NCT06642441

NCT06642441 Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06642441
Status Recruiting
Phase
Sponsor Jiuda Zhao
Condition Vitamin D
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-12-01
Primary Completion 2026-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Chemotherapy + vitamin D2Chemotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-12-01 with a primary completion date of 2026-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled Phase III trial was designed to evaluate the effect of vitamin D supplementation (VD) on chemotherapy side effects following adjuvant chemotherapy in breast cancer

Eligibility Criteria

Inclusion Criteria: 1. Age between 18 and 80 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 2. Primary diagnosis of breast cancer confirmed by preoperative pathological examination. 3. Serum 25(OH)D levels less than 20 ng/ml (50 nmol/L). 4. Patients who have not previously received chemotherapy and who plan to undergo at least 4 cycles of 5. Patients with adjuvant chemotherapy or combined targeted therapy. 6. Life expectancy of at least 6 months. 7. No other uncontrolled benign diseases at the time of recruitment. 8. All patients must have complete clinical medical records. 9. Willingness to voluntarily sign an informed consent form. Exclusion Criteria: 1. History of invasive breast cancer. 2. Prior systemic treatment for the treatment or prevention of breast cancer. 3. Known allergic reactions to vitamin D or calcium compounds. 4. Comorbidities that may affect vitamin D or calcium balance or bone health. 5. Vitamin D or calcium supplementation in the past 3 months. 6. Presence of other tumors. 7. Pregnant or lactating women. 8. Individuals who do not wish to participate in the study.

Contact & Investigator

Central Contact

Jiuda Zhao

✉ jiudazhao@126.com

📞 869716230893

Frequently Asked Questions

Who can join the NCT06642441 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Vitamin D. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06642441 currently recruiting?

Yes, NCT06642441 is actively recruiting participants. Contact the research team at jiudazhao@126.com for enrollment information.

Where is the NCT06642441 trial being conducted?

This trial is being conducted at Xining, China, Xining, China.

Who is sponsoring the NCT06642441 clinical trial?

NCT06642441 is sponsored by Jiuda Zhao. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology